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Abstract
Background: Existing studies have examined the high prevalence of LBP along with the high
treatment costs of patients with low back pain (LBP). Various factors have been shown to be
correlated or predictive of chronic or episodic LBP including the characteristics of the initial
episode, pain, comorbid conditions, psychosocial issues, and opiate use. This study replicates and
extends earlier studies by examining the association of patient characteristics including baseline
comorbidities with patterns of healthcare service use and cost.
Methods: This is a retrospective analysis of measures of comorbidities, healthcare use, and cost
for patients identified with LBP, stratified by the number of LBP episodes. Administrative data
associated with outpatient and hospital based care for the years 1996 through 2001, were used to
identify adult patients with LBP. LBP patients continuously enrolled for 12 months prior and 24
months after their initial LBP event were included in the study. A LBP episode was identified as the
number of 30-day periods where a patient had one or more healthcare events with a diagnosis
consistent with LBP. Chi-square and multivariate regression analyses were employed to estimate
the variation in utilization and costs.
Results: Of 16,567 patients enrolled, 67% were identified with only one LBP episode and 4.5% had
≥6. The prevalence of comorbidities, analgesic use, and healthcare service use, varied by the
number of back pain episodes. Diabetes, rheumatoid arthritis, anxiety, psychotic illness, depression,
use of opiates and NSAIDs were associated with significant incremental increases in costs (P <
.003).
Conclusion:  Physical and mental health co-morbidities and measures of analgesic use were
associated with chronicity, healthcare utilization and costs. Given the association of comorbidities
and cost for patients with LBP, management approaches that are effective across chronic illnesses
may prove to be beneficial for high cost patients identified with LBP.
Background
Treatment of low back pain (LBP) continues to be a signif-
icant medical and financial burden. While it is one of the
most common reasons for visiting a physician, observable
treatment patterns remain extremely variable and expen-
sive [1,2]. Much of the literature related to prevalence and
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economic burden associated with LBP has demonstrated
that most patients recover within a month of the initial
episode, but a small proportion go on to experience sig-
nificant disability related healthcare expense [3-8]. While
LBP is a common problem, consensus across the medical
community with respect to prevention and treatment
guidelines appears inconsistent [9]. In 1994, the Agency
for Health Research and Quality (AHRQ) released clinical
practice guidelines for adults with acute lower back prob-
lems. However, these guidelines are no longer viewed as
guidance for current medical practice [10].
While a small percentage of patients with chronic or epi-
sodic LBP account for a large proportion of cost, signifi-
cant variation exists with respect to both the definition
and treatment of chronic LBP [11-15]. Various factors
have been shown to be correlated or predictive of chronic
LBP including the characteristics of the initial episode,
pain, psychosocial issues, and occupation [11,16-18].
However, empirical evidence is mixed with respect to the
association between major psychopathology, such as
depression and substance abuse, and chronic LBP
[16,17,19]. The relationship between pain, analgesic use
and healthcare utilization related to LBP has also been
explored. A study by Vogt et al demonstrated that for
patients with LBP, opioid use was associated with high
volume usage of LBP healthcare services and that those
with psycohogenic pain were more likely to use opioids
[20]. Other comorbid conditions such as respiratory dis-
orders, heart disease and other musculoskeletal disorders
have been shown to have significant association with
chronic LBP [21,22]. Although physical and mental
health co-morbidities are believed to play a role in the
high cost cases there is little data describing their associa-
tion with specific patterns of healthcare utilization that
lead to higher costs [7].
In this study, we extend the current literature related to the
direct medical costs associated with LBP by examining the
number of back pain episodes, comorbidities, and analge-
sic use, and their relationship to healthcare utilization and
costs for a cohort of patients diagnosed with LBP. The pur-
pose of this study is to provide better understanding of the
characteristics of patients identified with a diagnosis of
LBP and their patterns of healthcare utilization and costs,
who were enrolled in an integrated healthcare delivery
system. We hypothesize that back pain patients with mul-
tiple co-morbidities are more likely to exhibit utilization
patterns consistent with chronic LBP that in turn drive
healthcare service utilization and costs.
Methods
Setting
We studied adult members of Kaiser Permanente Colo-
rado (KPCO). KPCO is a group model, closed panel, non-
profit HMO providing integrated healthcare services to
over 410,000 (covered enrollees), approximately 15 per-
cent of the insured population, in the Denver/Boulder,
Colorado metropolitan area. KPCO has over 550 physi-
cians in seventeen separate ambulatory medical offices
spread geographically across the greater metropolitan
area. Kaiser Permanente Colorado's Institutional Review
Board approved this project and the associated analyses of
data derived from the administrative databases.
Study population
We identified 16,567 patients from KPCO's inpatient and
outpatient based facility and professional claims, and
internal outpatient primary care and specialty care data-
bases for years 1996 through 2001. All patients were ≥18
years old at the time first index visit with a LBP diagnosis
during 1997 or 1998.
Low Back Pain diagnosis and index visit identification
A diagnosis of LBP was based on algorithm using Interna-
tional Classification of Diseases, Ninth Revision (ICD-9)
codes that was developed and validated at the University
of Washington and has been used in several previous
studies [20,22,23]. This algorithm consists of 66 ICD9
codes that include a broad array of diagnoses deemed con-
sistent with mechanical LBP. This algorithm excludes
patients if the back pain diagnosis was secondary to major
existing conditions: e.g. neoplasms, osteomyelitis, spinal
abscess, pregnancy, fracture, dislocation or vehicular acci-
dent. The index visit was defined as the first contact with
a healthcare provider in either an ambulatory or hospital
setting, resulting in a diagnosis, either primary or second-
ary, of LBP that was preceded by a 12 month period of
continuous enrollment with no evidence of LBP. Patients
were required to be continuously enrolled for a minimum
of 24 months after the index LBP event.
We created a proxy variable to capture the variation in the
number of back pain episodes across the study popula-
tion. This variable was defined as the number of 30-day
periods where a patient had one or more healthcare events
for LBP. Given the distribution of this variable (67.37%
had 1, 17.43% had 2, 10.72% had 3–5, and 4.8% had 6
to 22 episodes), for analytic purposes patients were
grouped into LBP episode categories of 1, 2, 3–5, and 6+.
In order to better understand the distribution of the diag-
noses associated with the patients' index LBP visit, we
used the four diagnostic categories noted in Vogt et al
(2005) [20]. These categories are (I) LBP without neuro-
logical involvement, (II) LBP with neurological involve-
ment, (IIIa) LBP caused by congenital lumbar spinal
structural disorders, (IIIb) LBP caused by acquired lumbar
spinal structural disorders, (IV) and LBP due to other
causes including postoperative issues. For analytic pur-
poses, categories IIIa and IIIb were grouped together.BMC Musculoskeletal Disorders 2006, 7:72 http://www.biomedcentral.com/1471-2474/7/72
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Utilization measures
We captured the following measures of utilization for 12
months prior, and 24-months subsequent to the index
back pain diagnosis: 1) outpatient care including primary
care, specialty care, physical therapy, and mental and
behavioral health; 2) all hospital based care including
inpatient stays, emergency department (ED) visits, and
observation stays of less than 24 hours in duration; 3) all
pharmaceutical dispenses; 4) major spinal-related radiol-
ogy procedures including CT and MRI.
We examined the variation in utilization patterns includ-
ing outpatient primary and specialty care, mental health,
physical therapy, imaging, pharmaceutical use, and hospi-
tal use by initially stratifying patients by the number of
LBP episodes. Given that it is often difficult to isolate back
pain specific healthcare resource use, we identified outpa-
tient and hospital based care that was more likely to be
related to back pain or musculoskeletal disorders. Outpa-
tient care provided in orthopedics, neurology, neurosur-
gery, rheumatology, and physiatry departments was
aggregated into an outpatient back pain specialty care cat-
egory. Other specialty care included cardiology, endo-
crinology, gastroenterology, ophthalmology, etc. We
classified hospital admissions that would fall into Major
Diagnostic Category (MDC) using Diagnosis Related
Groups (DRG). MDC 8 includes inpatient admissions
related "to diseases and disorders of the musculoskeletal system
and connective tissue" [24]. While this MCD in not specific
to LBP, most, if not all, LBP related admissions would be
captured in this diagnostic category.
Demographic and co-morbidity measures
Gender and age at the time of the index LBP event were
available from the electronic membership records. To
adjust for variation in health status and prevalence of
chronic conditions that could influence both healthcare
service utilization and costs during the observation
period, a pharmacy based risk adjustment system, called
RxRisk, was used to identify comorbidities [25]. The
RxRisk model, also referred to as the Chronic Disease
Score, is a clinically validated algorithm that classifies
patients into chronic disease categories based on prescrip-
tion drug fills [26]. The RxRisk (or CDS) system is a valid
and reliable predictor of future health services use and
future costs. Studies using this system demonstrate that it
performs as well as instruments based on International
Classification of Disease, 9th Revision, Clinical Modifica-
tion (ICD-9-CM) inpatient and outpatient diagnoses
[25,27]. Using the RxRisk algorithm, dichotomous varia-
bles were created in order to assess the contribution and
association of various comorbidities to utilization and
cost estimates. We estimated the prevalence of RxRisk
based comorbidities for the period 12 months prior to the
initial back pain index date.
We used American Hospital Formulary Service groups and
the National Drug Code system to identify and classify
physician prescribed pharmacy dispenses for the LBP pop-
ulation into categories of non-steroidal anti-inflamma-
tory drugs (NSAIDs) and opioids. We were not able to
capture over-the-counter dispenses fro NSAIDs. We esti-
mated the prevalence of use of these products for the 12
months prior and the 12 months after the index LBP visit.
Cost measurements
Using KPCO's cost management information system, we
estimated annualized costs of care for services provided
after the index back pain visit by type of utilization
resource including outpatient, inpatient, hospital, phar-
macy, and CT and MRI radiology procedures for the 24
months following the LBP index visit. This system allo-
cated health care cost for all internal services provided
directly by KPCO as well as claims for covered services
enrollees receive from contracted providers. Internal costs
are allocated by resource intensity weights (by service
department and procedure) using KPCO's general ledger.
Pharmacy costs are estimated using actual acquisition
costs and KPCO specific pharmacy dispensing costs. All
costs are reported in 1999 constant dollars. As a proxy for
total annualized costs in 2005 dollars, we used data from
the Medical care services component of the Consumer
Price Index to inflate the 1999 cost estimates into 2005
dollars [28].
Statistical analyses
Using chi-square tests of proportion, we compared pat-
terns of age, gender, co-morbidities, and utilization after
the initial index visit, categorized by the number of LBP
episodes. Given that hospital care may be the most costly
component of health service use, we employed logistic
regression analyses to examine the likelihood of an inpa-
tient admission based on age, gender and pre LBP index
visit comorbidities. Because the hospital admission event
may be correlated with the number of LBP episodes, we
did not include this variable in the final models. Separate
models predicting MDC 08 admissions were also esti-
mated.
In order to adjust for variation in health risk that may
influence cost estimates, cost is estimated as a function of
age, gender, comorbidities identified prior the back pain
index event, and as an extension of a study conducted by
Vogt et al, we also included variables capturing a dispense
for opioids or NSAIDs in the 12-month baseline period
prior to the index LBP event [20]. To avoid potential con-
founding with the dependent variable, the number of LBP
episodes were not included in the cost models. Consistent
with other cost studies, the dependent variable was the
total cost over the two year post index period, annualized
to avoid observations with zero charges and smooth indi-BMC Musculoskeletal Disorders 2006, 7:72 http://www.biomedcentral.com/1471-2474/7/72
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vidual year-to-year random variation and to minimize the
effect of outlier cost events on the overall cost distribution
[29,30]. The mean and standard deviation of annualized
costs, in 1999 dollars, for individuals in this cohort was
$2,780 and $6,008, respectively. Given the skewness of
the dependent variable, we used a weighted least squares
model instead of a standard linear model [30,31]. This
method involves creating a weight from the residuals
from the ordinary least-squares regression to adjust for
heteroskedastic error terms. This weighted least-squares
regression analysis provides unbiased regression coeffi-
cients and asymptotically efficient standard errors. In
addition, use of the weighted least-squares regression
analysis permitted health care costs associated with the
covariates in the model to remain in nominal values. The
use of nominal values eliminated the need to apply a var-
iance-stabilizing transformation to the dependent varia-
ble and subsequently retransform regression results to
obtain dollar values. Parameter estimates for each variable
may then be interpreted as the marginal or incremental
costs associated with patient falling into that particular
category.
Results
During the observation period of January 1, 1997 through
December 31, 1998, we identified a total of 16,567
patients ≥18 years, having an index visit with a diagnosis
of LBP, with no LBP related visits in the previous 12
months, and who were continuously enrolled for 12
months prior to and 24 months after the index visit. Table
1 describes the distribution of age, gender, index diagno-
sis categories, and RxRisk comorbidity categories, strati-
fied by the number of back pain episodes. A greater
proportion of the patients were females. The mean and
median age of the LBP population were 51.09 and 49.82,
respectively. Age is further described within 5 year catego-
ries in Table 1. As noted earlier, the majority of patients
identified (n = 11,161, 67.4%) experienced one LBP epi-
sode requiring contact with a KPCO provider during the
24 months of follow-up. Only 4.5% (n = 743) of the
patients had 6 or more documented episodes. Older age
was generally associated with higher numbers of LBP epi-
sodes (P < .001). No significant differences were found in
the gender distribution of patients by number of LBP epi-
sodes.
Eighty-one percent of all index visit diagnoses fell into cat-
egory I, LBP with no neurologic findings and 52 percent
of all index diagnoses were coded as Unspecific Backache
(ICD9 code 724.5). The distribution of the index visit
diagnoses varied significantly by the number of observed
LBP episodes (P < .001). Of those with 1 or more LBP epi-
sodes, 84% of the index visit diagnoses fell into category
I, versus 57% of patients with 6 or more.
Pharmacy based measures
We estimated prevalence for 14 comorbid conditions
using the RxRisk model (Table 1) for the 12 month period
prior to the LBP index visit. With the exception of cardio/
peripheral vascular disease (CVD/PVD), prevalence esti-
mates of all conditions typically increased by LBP episode
category.  P-values of < .0001 were derived from Chi-
square tests for all conditions with the exception of Diabe-
tes (P = .005), Thyroid disease (P = .003), and Psychosis
(P = .073). The range of prevalence estimates for patients
with 1 LBP episode relative 6 or more LBP episodes varied
from 4.8% – 5.1% for Diabetes, to 17.6% – 24.4% for
Hypertension.
Table 2 describes the prevalence of analgesic use in the 12
month period prior to the LBP index visit and in the 24
months after. For both NSAIDs and opioids, we found sig-
nificant variation (P < .001) in the prevalence analgesic
use, both before and after the index LBP visit and across
the LBP episode categories. LBP patients having 3–5
observed LBP episodes had the largest observed increase
in the prevalence of both NASIDS and opioids; 31.6% –
48.0% and 25.5% – 44.2%, respectively. While not shown
in Table 2, using a 24-month post observation period we
found that prevalence estimates continued to rise. Again,
the highest total and largest percent increase for the 24
month period was found for patients having 3–5 observed
LBP episodes (61.5% and 58.9%).
Utilization measures
Table 3 describes percent of LBP using outpatient and hos-
pital based care during the 24 month period after the
index LBP visit, stratified by the number of LBP episodes.
Significant variation (P < .001) across episode categories
was found for all utilization measures. The prevalence of
use did not always correlate with an increase in the
number of LBP episodes. Use of primary care outpatient
services was the highest (98%) for patients with 2 epi-
sodes, falling to 91.8% for patients with 6 or more epi-
sodes. Conversely, the percent of patients using outpatient
specialty care, outpatient back pain specialty care, mental
and behavioral healthcare, along with all hospital based
care increased as the number of back pain episodes
increased. For patients with only one LBP episode, the
percent of patients with one or more hospital admissions
or MDC 8 specific hospital admission, was 9.8% and
1.7%, respectively. For patients with patients with 6 or
more LBP episode, the percent of patients using these serv-
ices was 21.3% and 11.2%, respectively.
Results from the logistic regression model (Table 4) dem-
onstrated that the likelihood of an inpatient admission in
the two years subsequent to the index back pain event
increased with age. Those aged 65–75 were twice as likely
to have an admission (95% confidence interval [CI] =BMC Musculoskeletal Disorders 2006, 7:72 http://www.biomedcentral.com/1471-2474/7/72
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1.67–3.29). For patients aged 75–85 and patients over 85,
the odds increased to 4.0 and 5.46, respectively (CIs 2.82–
5.65, 3.58–8.33). If the initial back pain diagnosis was in
Category III or IV the likelihood also increased signifi-
cantly (CI = 1.24–1.76, 1.91–3.08). Psychosis increased
the likelihood by 72% (CI = 1.32–2.25), depression by
27% (CI = 1.13–1.46), asthma or COPD by 37% (CI =
1.18–1.58), diabetes by 102% (CI = 1.69–2.40), and heart
disease or hypertension by 72% (CI = 1.53–1.94). The use
of opiates or NSAIDs prior the index back pain event
increased the likelihood of an inpatient admission by
41% (CI = 1.25–1.59) and 19% (CI = 1.06–1.33), respec-
tively. The effects of older age, diagnoses category III and
IV, and NSAID use were even more pronounced for the
outcome of an MDC 8 admission. However, the effects of
the comorbidities noted above, were not significant.
While not included in the final models shown in Table 4,
the likelihood of any inpatient admission and an inpa-
tient admission for MDC 8, increased significantly by the
number of observed LBP episodes months in the 24-
month post index period. Relative to patients with only
one LBP episode, those with 6 or more were 90% more
Table 1: Distribution of Age, Gender Index LBP Diagnostic Category, and RxRisk Comorbidty Category by LBP Episodes for 16,567 
Patients Identified with LPB
Number of LBP Episodes
1 (11,161) 2 (2887) 3–5 (1776) 6+ (743) All (16,567) Chi-Sq P-value
(N) % % % % %
Age at First Back Pain
18–24 (752) 5.2 4.1 2.9 1.1 4.5
25–34 (1760) 11.3 10.1 8.8 7.3 10.6
35–44 (3668) 23.4 21.0 17.8 18.6 22.2
45–54 (4116) 24.6 24.0 27.0 27.1 24.8
55–64 (2759) 16.3 17.0 18.2 17.4 16.7
65–74 (2221) 12.2 15.2 16.0 18.7 13.4
75–84 (1051) 5.8 7.2 7.6 8.8 6.3
85+ (240) 1.4 1.5 2.0 1.2 1.5 <.0001
Male (7679) 46.9 45.6 45.4 43.3 46.4 0.087
Index Diagnosis Category
I (13,416) 84.0 81.2 72.0 56.7 81.0
II (1,592) 8.6 9.6 14.5 12.7 9.6
III: (1,114) 5.7 7.1 10.6 26.2 6.9
IV: (445) 2.7 2.2 2.9 4.6 2.5 <.0001
Prevalence Of RxRisk Comorbidity*
Anxiety (2026) 10.8 14.9 15.8 15.5 12.2 <.0001
Asthma/COPD (1978) 11.2 13.1 14.1 14.4 12.0 <.0001
Cardiac Disease (1134) 6.4 7.3 8.3 9.0 6.8 0.0005
CVD/PVD (495) 2.8 3.4 3.2 3.9 3.0 0.10
Depression (2227) 12.3 14.5 16.6 18.6 13.4 <.0001
Diabetes (854) 4.8 5.8 6.5 5.1 5.2 0.004
GI Disease (2100) 12.5 13.6 16.2 18.6 12.7 <.0001
HD/Hyperten (2327) 13.1 15.5 16.6 16.7 14.0 <.0001
Hyperlipidemia (1035) 5.7 6.8 7.1 10.0 6.2 <.0001
Hypertension (3212) 17.6 21.0 26.1 24.4 19.4 <.0001
Inflammation (2598) 14.0 18.3 20.6 18.6 15.6 <.0001
Psychosis (398) 2.2 2.6 3.0 3.1 2.4 0.073
Rheum Arthritis (732) 3.9 5.4 5.6 5.7 4.4 <.0001
Thyroid Disease (1301) 7.4 8.3 8.9 10.2 7.9 0.003
*Comorbidity abbreviations:
COPD = Chronic Obstructive Lung Disease
GI = Gastrointestial
HD/Hyperten = Heart Disease/Hypertension
Rheum= RheumatiodBMC Musculoskeletal Disorders 2006, 7:72 http://www.biomedcentral.com/1471-2474/7/72
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likely (P < .0001) to have any inpatient admission, and
almost 6 times more likely to have an admission for MDC
8 (P < .0001).
Cost analyses
Costs were initially estimated by category of service: Hos-
pital, outpatient, radiology, and pharmacy. Total annual-
ized average costs for the 24 months post LBP index visit,
estimated in 1999 constant dollars, were $45,974,305.
Using the Medical Care component of the CPI-U as a
proxy for changes in medical care service costs, this
number almost doubles to $70,934,545 in 2005 dollars.
The distribution of these costs by service use category, are
demonstrated in Figure 1. Primary care utilization was the
largest component of outpatient costs. Back pain specialty
care, mental health/chemical dependency, PT/OT, and
radiology cost were each all estimated to be over $1 mil-
lion dollars annually. Not unexpectedly, inpatient care
was the largest overall cost component, with an annual-
ized cost of over $16 million. Stratifying by the number of
back pain episodes, this translates to a total average
annual per patient cost of $2,410 ($3,718 in 2005 dol-
lars) for patients with 1 LBP episode, $3,114 ($4,805 in
2005 dollars) for patients with 2 LBP episodes,
$3,807($5,874 in 2005 dollars) for patients with 3–5 LBP
episodes, and $4,464 ($6,888 in 2005 dollars) for
patients with 6 or more LBP episodes.
Table 5 describes the results from the annualized total cost
weighted least squares regression model. As noted by the
R2, the model explained 31.63 percent of the variation in
annualized total costs. This level of explanatory power is
not inconsistent with other predictive cost models
[25,32,33]. Total annualized costs increased with female
gender, older age, and comorbidities and analgesic dis-
penses identified in the 12 month period prior to the
index visit. An estimated incremental increase of $2,001
was associated with the initial index diagnoses falling into
Category IV, or other non-specific conditions. At $2,799,
diabetes had the highest incremental cost estimate com-
pared to other comorbidities included in the model.
While rheumatoid arthritis was not significant in the inpa-
tient MDC 08 logistic models, the marginal cost of this
comorbidity was large and statistically significant
($1,625, p-value < .0001). Mental illness as proxied by the
RxRisk categories identifying anxiety, psychotic illness,
and depression in the period prior to the first back are also
associated with significant marginal costs. The use of opi-
Table 3: Service Use by Number of LBP Episodes in the 24 Months Post LBP Index Visit
1 (11,161) (% of 
Patients)
2 (2,887) (% of 
Patients)
3–5 (1,776) (% of 
Patients)
6+ (743) (% of 
Patients)
Total (16,567) (% 
of Patients)
Chi-Sq P-Value
Category *
Primary care 93.3 98.0 97.2 91.8 94.5 0.004
Specialty Care 41.2 47.6 57.8 59.4 44.9 <.0001
BP Spec Care* 12.9 17.6 27.4 35.3 16.3 <.0001
PT/OT 17.9 31.0 45.3 40.1 24.1 <.0001
Mental Health 9.3 12.0 10.9 13.7 10.1 <.0001
CT/MRI 4.6 14.0 34.0 37.3 10.9 <.0001
Spine X-ray 6.3 17.4 30.5 31.9 12.0 <.0001
ED/Observation 27.5 36.0 37.6 35.7 30.4 <.0001
Hospital Admit 9.8 12.1 14.2 21.3 11.2 <.0001
Hospital Admit for 
MDC 8
1.7 2.4 5.2 11.2 2.6 <.0001
*Back Pain Specialty includes orthopedics, neurology, neurosurgery, rheumatology, and physiatry outpatient departments. PT/OT refers to Physical 
Therapy or Occupational Therapy. ED/Observation refers hospital based care, < 24 hrs in duration in the Emergency Department or Observation 
Unit.
Table 2: Prevalence of Analgesic Use – 12 months Prior and 24 Months After the LBP Index Visit
% Any NSAID Pharmacy Dispense % Any Opioid Pharmacy Dispense
P r e  %P o s t  % P r e  %P o s t  %
Full Sample LBP 
Episodes
(16,567) 23.8 30.8 20.0 28.5
1 (11161) 21.4 25.0 18.0 24.0
2 (2887) 26.8 39.3 21.3 33.1
3–5 (1776) 31.6 48.0 25.5 44.2
6+ (743) 29.7 44.0 26.6 42.3BMC Musculoskeletal Disorders 2006, 7:72 http://www.biomedcentral.com/1471-2474/7/72
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ates and NSAIDs was also significant at (p-value <.0001)
$912 and $524, respectively.
Discussion
Our findings from this study are consistent with the
results found in other studies that examine treatment pat-
terns and costs associated with LBP. Consistent with sem-
inal study of Engel et al [7] that examined the predictors
of high healthcare costs for patients diagnosed with LBP,
we found that a small proportion of patients with multi-
ple LBP episodes had higher costs. Also consistent with
our results, in a study examining the relationship of
comorbidities and LBP episodes, Nordin et al (2002)
found that the presence of any comorbidity at the index
visit was associated with significantly longer duration of
LBP related work disability [22]. We also observed an
association of depression and psychopathology with an
increased number of LBP episodes and costs that was
demonstrated in three other studies [7,34,35].
The results show a relatively high prevalence of opioid use
in the population with multiple LBP episodes. While the
prevalence estimates of NSAID and opioids use that we
noted here are not inconsistent with those presented by
Vogt et al [20], evidence suggests that these agents may
pose a risk to patients [36-38].
Inpatient admissions for falling into the category of MDC
8 made up 23% of all inpatient admissions in the 24-
month post-index LPB event. It is not surprising that
many of the disease indicators which were associated with
any hospitalization were not significantly associated with
the MDC 8 admissions. The stronger association for dis-
penses for NSAID and opioids the baseline period (prior
to the index LBP event) in the MDC 8 models likely reflect
Average annual total costs for $16,567 LBP patients by cate- gory of service Figure 1
Average annual total costs for $16,567 LBP patients by cate-
gory of service.
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Table 4: Inpatient Logistic Regression Model
All Inpatient Admits Number of Events = 1,855 MDC 08 Inpatient Admits Number of Events = 433
Variable Label Odds Ratio Confidence Intervals Odds Ratio Confidence Intervals
Male (Female ref) 1.09 0.98–1.2 1.22 0.99–1.49
Age 18–24(ref) - -
Age 25 – 34 0.87 0.60–1.28 0.47 0.14–1.55
Age 35 – 44 0.81 0.60–1.26 1.45 0.57–3.71
Age 45 – 54 1.16 0.83–1.62 2.09 0.83–5.23
Age 55 – 64 1.56 1.12–2.18 3.45 1.38–8.63
Age 65 – 74 2.35 1.67–3.29 5.11 2.04–12.76
Age 75 – 85 4.00 2.82–5.65 11.26 4.50–28.21
Age > 85 5.46 3.58–8.33 12.57 4.67–34.16
Dx Category II (I=ref) 1.00 0.84–1.19 1.64 1.22–2.20
Dx Category III 1.48 1.24–1.76 1.74 1.27–2.39
Dx Category IV 2.43 1.91–3.08 5.64 4.09–7.78
Anxiety 1.14 0.99–1.32 1.17 0.89–1.53
Psychosis 1.72 1.32–2.25 1.38 0.81–2.35
Depression 1.27 1.13–1.46 0.96 0.74–1.27
Asthma/COPD 1.37 1.18–1.58 1.22 0.92–1.60
Diabetes 2.02 1.69–2.40 1.14 0.80–1.63
GI Disorder 1.12 0.97–1.28 1.10 0.86–1.43
HD/Hypertension 1.72 1.53–1.94 1.19 0.95–1.49
Rheumatoid Arthritis 1.36 1.10–1.68 1.11 0.74–1.65
Opiate dispense 1.41 1.25–1.59 1.27 1.02–1.59
NSAID dispense 1.19 1.06–1.33 1.76 1.43–2.17
Comorbidity abbreviations: COPD = Chronic Obstructive Lung Disease, GI = Gastrointestinal, HD/Hyperten=Heart Disease/HypertensionBMC Musculoskeletal Disorders 2006, 7:72 http://www.biomedcentral.com/1471-2474/7/72
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elements of severity contributing to the MDC 8 admis-
sions.
This study has several limitations. It relies on administra-
tive data rather than on patient report of the initial and
subsequent LBP episodes. It also lacks self-report data
related to pain and disability. While we limited the sam-
ple to those with no documented contact with a health-
care provider associated with LBP, we cannot assume that
the index visit is the first episode of LBP for the popula-
tion that we studied. In addition, our measure of the
number of LBP episodes, number of 30 day periods with
one or more LBP events, may not be consistent with epi-
sode definitions in other studies and we cannot be sure
they represent separate unique episodes [11,12,16]. This
variable may also be capturing patient visits for multiple
acute episodes, particularly if they occur at the large time
intervals. A value of 2 could reflect two visits a week about
one on each site of the window border or two visits in a
year apart. In this analysis, LBP episodes are likely to cap-
ture elements of both chronicity and severity. What these
elements may imply about a patient's low back pain con-
dition is not examined in this manuscript. Our capture of
NSAIDs was limited to physician prescribed dispenses.
We did not observe over-the-counter purchases of
NSAIDs. We only examined factors associated with chro-
nicity and cost, rather than estimating a prediction model
of patients who would go on to have multiple LBP epi-
sodes related high costs. We limited the cost analyses to
the direct medical costs borne by the payer or insurer.
These cost estimates did not include complementary and
alternative medical treatments including chiropractry,
acupuncture, or massage therapy, which may now be a
covered benefit for some LBP patients [39]. We did not
examine the indirect costs to the patient associated with
pain, disability, loss of work and leisure activities, etc. We
also did not examine the indirect costs to society associ-
ated with absentisem and loss of productivity.
Conclusion
To our knowledge, this is the largest study to examine the
distribution of comorbidities and analgesic use, the
number of LBP episodes and their association with
healthcare utilization and costs. We demonstrated that
most measures of utilization and annual total costs
increased with age, comorbidities, use of analgesics, and
the number of LBP episode months.
We estimated that in 2005 dollars the annual direct med-
ical costs for 16,567 patients who present with LBP was
$70,934,545, or on average $357 per member, per month.
These patients are very expensive and they are very com-
plex with respect to the prevalence and distribution of
other comorbidities. Our utilization estimates demon-
strated that those with most LBP episodes were the lowest
users of primary care, but the highest users of all forms of
specialty care. The findings from this study, reinforce the
suggestions by Carey and Freburger (2005), and Nordin et
Table 5: Annualized Total Cost Weight Least Squares Regression Model N= 16,547 Adjusted R2 = 0.3163
Variable Label Parameter Estimate Standard Error P-Value
Intercept -1241.14 119.66 <.0001
Male -294.21 50.95 <.0001
Age 25 – 34 -164.83 137.67 0.23
Age 35 – 44 -109.54 126.44 0.81
Age 45 – 54 30.81 132.77 0.02
Age 55 – 64 302.04 132.77 <.0001
Age 65 – 74 1203.64 138.42 <.0001
Age 75 – 85 1936.07 156.66 <.0001
Age > 85 1800.55 238.81 <.0001
Diagnosis Category II 120.44 83.86 0.15
Diagnosis Category III 156.54 99.26 0.11
Diagnosis Category IV 2001.02 152.28 <.0001
Anxiety 827.58 79.58 <.0001
Psychotic Illness 1571.03 162.47 <.0001
Depression 1430.44 76.67 <.0001
Asthma/COPD 660.79 79.00 <.0001
Diabetes 2937.67 114.06 <.0001
GI Disorder 1013.77 76.72 <.0001
HD/Hypertension 1339.12 63.83 <.0001
Rheumatoid Arthritis 1625.42 124.42 <.0001
Thyroid Disorder 250.62 94.15 0.007
Opiate dispense 911.93 64.47 <.0001
NSAID dispense 524.73 59.74 <.0001
*Reference Categories include in the intercept parameter estimate were Female, Age 18–25, and Diagnosis Category I.BMC Musculoskeletal Disorders 2006, 7:72 http://www.biomedcentral.com/1471-2474/7/72
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(2002) that special attention to high utilizers, and those
with other chronic conditions may improve the outcomes
for these patients, and possibly reduce both the short and
long term costs associated with this condition [40,22].
Given the general lack of consensus on guidelines for the
management of back pain, and the comorbidity patterns
that we found, it would make sense to rely on manage-
ment approaches that seem effective across chronic ill-
nesses. To our knowledge, the Chronic Care Model [41]
has received the greatest attention and research among
general evidence-based approaches to disease manage-
ment. The Chronic Care Model also seems particularly
applicable with respect to LBP due to its emphasis on self-
management and self-management support [42].
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